FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to oncology. At the stages of dynamic observation after the treatment in the blood serum, the level of the protein of the delta-like non-canonical Notch ligand 1 DLK1 is determined. With a protein content of more than 0.322 ng/ml, a high risk of relapse is predicted. With a protein content of less than or equal to 0.322 ng/ml, a low risk of recurrence is predicted.
EFFECT: invention provides improved accuracy of early diagnosis of disease recurrence.
1 cl, 1 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR INDICATING THE EFFECTIVENESS OF COMBINED ADAPTIVE STEREOTACTIC RADIOTHERAPY WITH BEVACIZUMAB IN MEN WITH MALIGNANT BRAIN GLIOMAS | 2023 |
|
RU2801419C1 |
| METHOD FOR PREDICTION OF PROBABILITY OF POSSIBLE EXECUTION OF OPTIMUM CYTOREDUCTIVE OPERATION IN PATIENTS WITH DISSEMINATED FORMS OF OVARIAN CANCER | 2017 |
|
RU2637399C1 |
| TEST SYSTEM FOR DETERMINING IDH 1/2 GENE STATUS IN GLIAL TUMOR TISSUES | 2023 |
|
RU2823028C1 |
| METHOD FOR PREDICTION OF DEVELOPMENT OF PROGRESSION IN A LONG PERIOD IN PATIENTS WITH SQUARE CELL CANCER OF THE HEAD AND NECK | 2021 |
|
RU2765013C1 |
| METHOD FOR PREDICTING THE DURATION OF THE RELAPSE-FREE PERIOD OF SOFT TISSUE SARCOMAS OF THE EXTREMITIES IN MIDDLE-AGED AND ELDERLY WOMEN | 2022 |
|
RU2778616C1 |
| METHOD FOR PREDICTION OF RISK OF TUMOUR PROGRESSION IN PATIENTS WITH OVARIAN CANCER | 2023 |
|
RU2816339C1 |
| METHOD FOR PREDICTING THE COURSE OF LOW-DIFFERENTIATED GLIAL TUMORS BASED ON A CYTOKINE MICROENVIRONMENT | 2020 |
|
RU2741690C1 |
| METHOD FOR PREDICTION OF NEOADJUVANT CHEMOTHERAPY EFFECTIVENESS IN PATIENTS WITH DISSEMINATED FORMS OF OVARIAN CANCER | 2017 |
|
RU2637410C1 |
| METHOD OF TREATMENT OF MALIGNANT BRAIN TUMORS | 2015 |
|
RU2578472C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF TUMOR RECURRENCE IN PAPILLARY THYROID CANCER | 2022 |
|
RU2795086C1 |
